Outcomes of sword swallowing and pharmaceutical step-therapy interventions.
Curtiss
Frederic R
FR
D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004608:Eligibility Determination; D017048:Health Care Costs; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics; D007345:Insurance Claim Review / Q000191:economics / Q000458:organization & administration*; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D008329:Managed Care Programs / Q000191:economics / Q000458:organization & administration*; D017063:Outcome Assessment, Health Care; D016896:Treatment Outcome; D014481:United States
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents